Manufacturing documents: MFR, BMR, PVP, PVR and more

Agree a product-specific review pack

Give Walter the composition, strength, dosage form, intended market, review purpose and proposed site if known. Ask QA to identify available documents, their current revisions and permitted access. This checklist helps organise supplier qualification, transfer and batch-supply discussions; it is not a statement that Walter holds or can release every listed record.

Select documents for the actual product, process, pack, market and project stage. A sterile-product study, for example, is not automatically relevant to a non-sterile tablet. The referenced WHO, EU and FDA guidance explains the underlying document areas; the applicable local and destination-market requirements must be confirmed for your project.

Distinguish plans, results and access

A protocol sets out the planned work and acceptance criteria; an approved report records the outcome and conclusions. Ask for both where applicable, including relevant deviations and follow-up actions. PVP means Process Validation Protocol and PVR means Process Validation Report in this guide. Confirm local abbreviations with the document owner.

A master instruction, a blank batch-record template and an executed batch record serve different purposes. State which you need, name the relevant product/batches, and agree whether review will use a full document, redacted copy, summary or supervised access.

Site, licence and audit scope

Manufacturing licence and product permissions — confirm the proposed site, exact presentation, authorised activities and current scope.
GMP (Good Manufacturing Practice) certificates and SMF (Site Master File) — review site identity, certificate validity and the facility’s quality and manufacturing arrangements.
Supplier-qualification questionnaire, inspection or audit summaries and responses — agree the relevant scope and evidence of action closure; confidential inspection records may need controlled access.

Reference: WHO GMP: main principles

Manufacturing, packing and batch release

MFR (Master Formula Record) and master manufacturing instructions — the approved formula and instructions for the defined product and batch size.
Master packing instructions — the approved components, artwork, line checks and reconciliation requirements for the agreed pack.
BMR (Batch Manufacturing Record), BPR (Batch Packing Record) and release records — identify whether you need blank templates or executed records for named batches, including in-process checks and reconciliation.

Reference: EU GMP Chapter 4: documentation

Process validation and continued verification

PVP (Process Validation Protocol) — the approved study plan, including batch scope, critical parameters, sampling, tests and acceptance criteria.
PVR (Process Validation Report) — the executed results, deviations, conclusions and approval against that protocol. A protocol alone does not establish a successful outcome.
PPQ (Process Performance Qualification) protocol/report and continued process verification records — request the applicable lifecycle evidence and trend review. Terminology can differ; PVP/PVR and PPQ documents may cover overlapping work.

Reference: FDA: process validation principles and practices

Equipment, facilities and utilities

VMP (Validation Master Plan) — the site’s validation programme and status. URS (User Requirements Specification), DQ (Design Qualification), IQ (Installation Qualification), OQ (Operational Qualification) and PQ (Performance Qualification) — the applicable qualification records.
Calibration, maintenance and utility qualification/monitoring records — scope equipment, heating/ventilation/air conditioning (HVAC), water and gases to the proposed process; not every utility applies to every product.

Reference: EU GMP Annex 15: qualification and validation

Cleaning, carryover and hold times

CVP (Cleaning Validation Protocol) and CVR (Cleaning Validation Report) — include the equipment/product grouping, worst-case rationale, residue limits, sampling and swab/rinse recovery evidence.
Health-based exposure limits (HBEL) or permitted daily exposure (PDE) assessments, where applicable — review the basis for carryover controls, alongside relevant cleaning and process hold-time studies.

Reference: EU GMP Annex 15: qualification and validation

Specifications and analytical evidence

Specifications, MOA (Method of Analysis) and STP (Standard Testing Procedure) — agree material, in-process and finished-product tests, standards and acceptance limits. Here MOA means the test method, not mechanism of action.
COA (Certificate of Analysis) and supporting laboratory records — identify the material/product, batch and approved specification. A specimen COA is not a release certificate for a future batch.
Analytical method validation, verification and transfer protocols/reports — request the applicable evidence, reference-standard qualification and relevant out-of-specification or out-of-trend investigations.

Reference: EU GMP Chapter 6: quality control · EU GMP Chapter 4: documentation

Stability, packaging and transport

Stability protocols, reports and ongoing commitments — identify the formula, batches, pack, conditions and available time points supporting the proposed storage statement and shelf life; include in-use or reconstitution studies where relevant.
Packaging specifications, approved artwork and compatibility evidence — agree the container/closure, seal checks and applicable packaging qualification; ask about transport studies for the intended distribution conditions.

Reference: EU GMP Chapter 6: quality control · EU GMP Annex 15: qualification and validation

Development and technology transfer

Product development report and technology-transfer protocol/report — define the sending and receiving sites, formula/process knowledge, responsibilities, acceptance criteria and transfer outcome.
Gap assessment, quality risk assessment and control strategy — identify critical quality attributes (CQA), critical process parameters (CPP), scale-up assumptions and remaining work for the proposed site.

Reference: WHO: technology transfer in pharmaceutical manufacturing

Quality reviews, investigations and changes

PQR (Product Quality Review) / APR (Annual Product Review) — review product performance, recurring issues and follow-up actions for an agreed period; naming and scope depend on the quality system and market.
Deviation, change-control and CAPA (Corrective and Preventive Action) records — request relevant investigation summaries, impact assessments and evidence that actions were effective.
OOS (Out of Specification), OOT (Out of Trend), complaints and recall summaries — agree the product/site scope, alongside relevant SOPs (Standard Operating Procedures) and training evidence.

Reference: EU GMP Chapter 1: pharmaceutical quality system · WHO GMP: main principles

Material suppliers and impurity risks

API (Active Pharmaceutical Ingredient) and excipient qualification records — request supplier approval, traceability, specifications and material COAs for the intended sources.
Impurity risk assessments and supporting test/control evidence — cover relevant nitrosamines, elemental impurities and residual solvents for the product, materials and process.
Animal-origin declarations and TSE (Transmissible Spongiform Encephalopathy) / BSE (Bovine Spongiform Encephalopathy) evidence, where relevant — scope the request to materials such as animal-derived gelatin; not a blanket requirement for every formulation.

Reference: WHO GMP: main principles · FDA: control of nitrosamine impurities · ICH Q3D(R2): elemental impurities · ICH Q3C(R8): residual solvents · EMA: animal-origin materials and TSE risk

Sterile-product evidence, where applicable

CCS (Contamination Control Strategy) and environmental/personnel monitoring records — scope the controls to the proposed sterile process and facility.
Aseptic process simulation (media-fill), sterilisation and filtration validation reports — request the studies applicable to the chosen manufacturing method; not every sterile process uses all three.
Sterility, bacterial endotoxin and container-closure integrity methods/results — confirm product applicability, validation and batch or study scope. These are conditional requests, not requirements for ordinary non-sterile tablets.

Reference: EU GMP Annex 1: sterile medicinal products

Computerised systems and data integrity

CSV (Computerised System Validation) lifecycle evidence — request the relevant system scope, requirements, risk assessment, testing and approval.
Data-integrity and electronic-record procedures — review access controls, audit-trail reviews, backup/restore checks, record retention and business-continuity arrangements within the agreed audit scope.

Reference: EU GMP Annex 11: computerised systems

Market-specific regulatory support

Product dossier / Common Technical Document (CTD) quality sections — agree the target-market format and the product/site evidence available for that submission.
API master-file support or CEP (Certificate of Suitability to European Pharmacopoeia monographs) — confirm applicability, current version and access permissions from the document owner. Bioequivalence reports or biowaiver justification need product- and market-specific assessment.
CPP/CoPP (Certificate of a Pharmaceutical Product) — ask about the relevant authority-issued certificate where required; a certificate does not itself establish approval in the destination country.

Reference: WHO: assessment of generic finished pharmaceutical products · WHO: model Certificate of a Pharmaceutical Product

Quality agreement and access arrangements

Quality agreement / technical agreement — assign manufacturing, laboratory, release, deviation, change, complaint, recall, subcontracting and record-retention responsibilities between the parties.
Audit and document-access arrangements — agree contacts, timelines, review format and confidentiality. An NDA does not by itself authorise release of third-party intellectual property or other customers’ records.

Reference: FDA: contract manufacturing quality agreements

What can Walter provide for review?

Walter’s quality and regulatory teams confirm availability, applicability, document ownership and access conditions for the proposed engagement. Some records may be planned rather than completed for a new product or transfer; identify these gaps and agree the required work and timing.

Executed records, proprietary methods, inspection information and third-party documents may require an NDA, redaction or controlled review. An NDA alone does not authorise release of every record or of another customer’s information.

Match the request to the project stage

Initial screening: product identity, proposed site, permission scope and a document availability list.
Supplier qualification: site and quality-system evidence, audit scope and relevant controlled documents.
Development or transfer: formula/process knowledge, analytical methods, specifications, transfer and validation plans, with agreed responsibilities.
Batch supply and lifecycle: agreed executed batch, testing and release records, stability commitments, review trends and change notifications.

Use this wording in your enquiry

“For [composition, strength and dosage form] intended for [market], please confirm the proposed site and the documents available for [supplier qualification / technology transfer / batch review]. Please identify applicable items from the manufacturing-document checklist, including PVP/PVR, MFR, BMR, BPR, methods, COA and stability evidence. For each item, confirm the revision, product/batch scope, review format, access conditions, timing and any work still required.”